Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization
En el presente estudio se evaluó la potencia in vitro de la ceftazidima y la cefepima en cepas de Pseudomonas aeruginosa resistentes a los carbapenemes recogidas en el marco de un programa mundial de vigilancia, y se valoraron las implicaciones farmacodinámicas utilizando la farmacocinética poblacio...
- Autores:
-
Aktaş, Elif
Gill, Christian M.
Cantón, Rafael
Carmeli, Yehuda
Martinez, Octavio V.
Bourassa, Lori
Brink, Adrian
Burnham, Carey Ann D.
Falcone, Marco
Marchese, Anna
Martinez, Octavio
Pournaras, Spyros
Seifert, Harald
Thabit, Abrar K.
Villegas, Maria Virginia
Westblade, Lars F.
Nicolau, David P.
Alfouzan, Wadha
Kiffer, Carlos
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2021
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/9642
- Palabra clave:
- Resistencia al carbapenem
Cefepime
Ceftazidima
Farmacodinámica
Farmacocinética
Pseudomonas aeruginosa
Carbapenem resistance
Cefepime
Ceftazidime
Pharmacodynamics
Pharmacokinetics
Pseudomonas aeruginosa
- Rights
- closedAccess
- License
- http://purl.org/coar/access_right/c_14cb
id |
UNBOSQUE2_36892acc9b2654331259ea2c5acf8eab |
---|---|
oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/9642 |
network_acronym_str |
UNBOSQUE2 |
network_name_str |
Repositorio U. El Bosque |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
dc.title.translated.spa.fl_str_mv |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
title |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
spellingShingle |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization Resistencia al carbapenem Cefepime Ceftazidima Farmacodinámica Farmacocinética Pseudomonas aeruginosa Carbapenem resistance Cefepime Ceftazidime Pharmacodynamics Pharmacokinetics Pseudomonas aeruginosa |
title_short |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
title_full |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
title_fullStr |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
title_full_unstemmed |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
title_sort |
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization |
dc.creator.fl_str_mv |
Aktaş, Elif Gill, Christian M. Cantón, Rafael Carmeli, Yehuda Martinez, Octavio V. Bourassa, Lori Brink, Adrian Burnham, Carey Ann D. Falcone, Marco Marchese, Anna Martinez, Octavio Pournaras, Spyros Seifert, Harald Thabit, Abrar K. Villegas, Maria Virginia Westblade, Lars F. Nicolau, David P. Alfouzan, Wadha Kiffer, Carlos |
dc.contributor.author.none.fl_str_mv |
Aktaş, Elif Gill, Christian M. Cantón, Rafael Carmeli, Yehuda Martinez, Octavio V. Bourassa, Lori Brink, Adrian Burnham, Carey Ann D. Falcone, Marco Marchese, Anna Martinez, Octavio Pournaras, Spyros Seifert, Harald Thabit, Abrar K. Villegas, Maria Virginia Westblade, Lars F. Nicolau, David P. Alfouzan, Wadha Kiffer, Carlos |
dc.contributor.orcid.none.fl_str_mv |
Burnham, Carey Ann D. [0000-0002-1137-840X] Falcone, Marco [0000-0003-3813-8796] Kiffer, Carlos Roberto Veiga [0000-0003-1122-0693] Marchese, Anna [0000-0002-3188-3518] Alfouzan, Wadha [0000-0002-4501-5316] Bourassa, Lori [0000-0001-8903-5274] Canton, Rafael [0000-0003-1675-3173] Thabit, Abrar K. [0000-0002-0369-9094] Nicolau, David P. [0000-0002-4148-0165] |
dc.subject.spa.fl_str_mv |
Resistencia al carbapenem Cefepime Ceftazidima Farmacodinámica Farmacocinética Pseudomonas aeruginosa |
topic |
Resistencia al carbapenem Cefepime Ceftazidima Farmacodinámica Farmacocinética Pseudomonas aeruginosa Carbapenem resistance Cefepime Ceftazidime Pharmacodynamics Pharmacokinetics Pseudomonas aeruginosa |
dc.subject.keywords.spa.fl_str_mv |
Carbapenem resistance Cefepime Ceftazidime Pharmacodynamics Pharmacokinetics Pseudomonas aeruginosa |
description |
En el presente estudio se evaluó la potencia in vitro de la ceftazidima y la cefepima en cepas de Pseudomonas aeruginosa resistentes a los carbapenemes recogidas en el marco de un programa mundial de vigilancia, y se valoraron las implicaciones farmacodinámicas utilizando la farmacocinética poblacional previamente publicada. Cuando eran susceptibles, las CMI se situaban en el extremo superior de la distribución tanto para ceftazidima como para cefepima, por lo que se requerían 6 g/día para lograr perfiles farmacodinámicos óptimos. Estos resultados deben tenerse en cuenta en la clínica y para la aplicación de los puntos de rotura de susceptibilidad CLSI. |
publishDate |
2021 |
dc.date.issued.none.fl_str_mv |
2021 |
dc.date.accessioned.none.fl_str_mv |
2023-01-19T13:56:24Z |
dc.date.available.none.fl_str_mv |
2023-01-19T13:56:24Z |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.local.none.fl_str_mv |
Artículo de revista |
dc.type.hasversion.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coarversion.none.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
publishedVersion |
dc.identifier.issn.none.fl_str_mv |
0066-4804 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/9642 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1128/AAC.01204-21 |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
dc.identifier.repourl.none.fl_str_mv |
repourl:https://repositorio.unbosque.edu.co |
identifier_str_mv |
0066-4804 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co |
url |
http://hdl.handle.net/20.500.12495/9642 https://doi.org/10.1128/AAC.01204-21 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofseries.spa.fl_str_mv |
Antimicrobial Agents and Chemotherapy, 0066-4804, Vol 65, Num 11, 2021, e01204-21 |
dc.relation.uri.none.fl_str_mv |
https://journals.asm.org/doi/10.1128/AAC.01204-21 |
dc.rights.accessrights.none.fl_str_mv |
info:eu-repo/semantics/closedAccess http://purl.org/coar/access_right/c_14cb Acceso cerrado |
eu_rights_str_mv |
closedAccess |
rights_invalid_str_mv |
http://purl.org/coar/access_right/c_14cb Acceso cerrado |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
American Society for Microbiology |
dc.publisher.journal.spa.fl_str_mv |
Antimicrobial Agents and Chemotherapy |
institution |
Universidad El Bosque |
bitstream.url.fl_str_mv |
https://repositorio.unbosque.edu.co/bitstreams/071c8d7a-5d2d-447d-9fb2-431617ee1ff4/download https://repositorio.unbosque.edu.co/bitstreams/05897b29-065a-4cb1-89b8-67ea552a6b8e/download https://repositorio.unbosque.edu.co/bitstreams/3fe331bd-9f63-4147-8c43-1c5fc4087a6f/download https://repositorio.unbosque.edu.co/bitstreams/a9f15cf8-30b9-4b19-ac7f-ac68729fa416/download |
bitstream.checksum.fl_str_mv |
6b98811fd3ec84055da741d071f54949 8a4605be74aa9ea9d79846c1fba20a33 54a83ca903b14f148572c9cfc282aadf a98da235cb49bd06dbe3aae274ef3dbe |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad El Bosque |
repository.mail.fl_str_mv |
bibliotecas@biteca.com |
_version_ |
1828164621713801216 |
spelling |
Aktaş, ElifGill, Christian M.Cantón, RafaelCarmeli, YehudaMartinez, Octavio V.Bourassa, LoriBrink, AdrianBurnham, Carey Ann D.Falcone, MarcoMarchese, AnnaMartinez, OctavioPournaras, SpyrosSeifert, HaraldThabit, Abrar K.Villegas, Maria VirginiaWestblade, Lars F.Nicolau, David P.Alfouzan, WadhaKiffer, CarlosBurnham, Carey Ann D. [0000-0002-1137-840X]Falcone, Marco [0000-0003-3813-8796]Kiffer, Carlos Roberto Veiga [0000-0003-1122-0693]Marchese, Anna [0000-0002-3188-3518]Alfouzan, Wadha [0000-0002-4501-5316]Bourassa, Lori [0000-0001-8903-5274]Canton, Rafael [0000-0003-1675-3173]Thabit, Abrar K. [0000-0002-0369-9094]Nicolau, David P. [0000-0002-4148-0165]2023-01-19T13:56:24Z2023-01-19T13:56:24Z20210066-4804http://hdl.handle.net/20.500.12495/9642https://doi.org/10.1128/AAC.01204-21instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coEn el presente estudio se evaluó la potencia in vitro de la ceftazidima y la cefepima en cepas de Pseudomonas aeruginosa resistentes a los carbapenemes recogidas en el marco de un programa mundial de vigilancia, y se valoraron las implicaciones farmacodinámicas utilizando la farmacocinética poblacional previamente publicada. Cuando eran susceptibles, las CMI se situaban en el extremo superior de la distribución tanto para ceftazidima como para cefepima, por lo que se requerían 6 g/día para lograr perfiles farmacodinámicos óptimos. Estos resultados deben tenerse en cuenta en la clínica y para la aplicación de los puntos de rotura de susceptibilidad CLSI.The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.application/pdfengAmerican Society for MicrobiologyAntimicrobial Agents and ChemotherapyAntimicrobial Agents and Chemotherapy, 0066-4804, Vol 65, Num 11, 2021, e01204-21https://journals.asm.org/doi/10.1128/AAC.01204-21Resistencia al carbapenemCefepimeCeftazidimaFarmacodinámicaFarmacocinéticaPseudomonas aeruginosaCarbapenem resistanceCefepimeCeftazidimePharmacodynamicsPharmacokineticsPseudomonas aeruginosaElevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose OptimizationElevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose OptimizationArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/closedAccesshttp://purl.org/coar/access_right/c_14cbAcceso cerradoORIGINALAAC.01204-21.pdfAAC.01204-21.pdfElevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimizationapplication/pdf559177https://repositorio.unbosque.edu.co/bitstreams/071c8d7a-5d2d-447d-9fb2-431617ee1ff4/download6b98811fd3ec84055da741d071f54949MD53LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/05897b29-065a-4cb1-89b8-67ea552a6b8e/download8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILAAC.01204-21.pdf.jpgAAC.01204-21.pdf.jpgIM Thumbnailimage/jpeg12098https://repositorio.unbosque.edu.co/bitstreams/3fe331bd-9f63-4147-8c43-1c5fc4087a6f/download54a83ca903b14f148572c9cfc282aadfMD54TEXTAAC.01204-21.pdf.txtAAC.01204-21.pdf.txtExtracted texttext/plain21491https://repositorio.unbosque.edu.co/bitstreams/a9f15cf8-30b9-4b19-ac7f-ac68729fa416/downloada98da235cb49bd06dbe3aae274ef3dbeMD5520.500.12495/9642oai:repositorio.unbosque.edu.co:20.500.12495/96422024-02-07 10:45:42.677restrictedhttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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 |